X4 Pharmaceuticals secured FDA agreement to reduce its late-stage trial enrollment by 126 patients, with data expected mid-2028. This regulatory alignment supports the company's expanded mavorixafor franchise for antibody deficiencies.
X4 Pharmaceuticals secured FDA agreement to reduce its late-stage trial enrollment by 126 patients, with data expected mid-2028. This regulatory alignment supports the company's expanded mavorixafor franchise for antibody deficiencies.